EUKEDOS SPA (EUK.MI) Stock Fundamental Analysis

BIT:EUK • IT0004818297

0.685 EUR
-0.02 (-2.84%)
Last: Jan 26, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to EUK. EUK was compared to 29 industry peers in the Health Care Providers & Services industry. While EUK is still in line with the averages on profitability rating, there are concerns on its financial health. EUK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year EUK has reported negative net income.
  • EUK had a positive operating cash flow in the past year.
  • In multiple years EUK reported negative net income over the last 5 years.
  • EUK had a positive operating cash flow in each of the past 5 years.
EUK.MI Yearly Net Income VS EBIT VS OCF VS FCFEUK.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

1.2 Ratios

  • EUK has a Return On Assets of -0.65%. This is in the lower half of the industry: EUK underperforms 78.79% of its industry peers.
  • With a Return On Equity value of -3.97%, EUK is not doing good in the industry: 78.79% of the companies in the same industry are doing better.
  • EUK has a worse Return On Invested Capital (2.64%) than 72.73% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for EUK is below the industry average of 6.14%.
  • The 3 year average ROIC (2.58%) for EUK is below the current ROIC(2.64%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -0.65%
ROE -3.97%
ROIC 2.64%
ROA(3y)0.12%
ROA(5y)-0.11%
ROE(3y)0.54%
ROE(5y)-0.64%
ROIC(3y)2.58%
ROIC(5y)2.22%
EUK.MI Yearly ROA, ROE, ROICEUK.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 -4 -6

1.3 Margins

  • With an excellent Operating Margin value of 9.80%, EUK belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • EUK's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 95.00%, EUK belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
  • In the last couple of years the Gross Margin of EUK has remained more or less at the same level.
Industry RankSector Rank
OM 9.8%
PM (TTM) N/A
GM 95%
OM growth 3Y-2.47%
OM growth 5Y3.88%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y0.24%
EUK.MI Yearly Profit, Operating, Gross MarginsEUK.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EUK is destroying value.
  • The number of shares outstanding for EUK remains at a similar level compared to 1 year ago.
  • EUK has about the same amout of shares outstanding than it did 5 years ago.
  • EUK has a better debt/assets ratio than last year.
EUK.MI Yearly Shares OutstandingEUK.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
EUK.MI Yearly Total Debt VS Total AssetsEUK.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • EUK has an Altman-Z score of 0.28. This is a bad value and indicates that EUK is not financially healthy and even has some risk of bankruptcy.
  • EUK has a Altman-Z score of 0.28. This is in the lower half of the industry: EUK underperforms 75.76% of its industry peers.
  • A Debt/Equity ratio of 2.94 is on the high side and indicates that EUK has dependencies on debt financing.
  • With a Debt to Equity ratio value of 2.94, EUK is not doing good in the industry: 75.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.94
Debt/FCF N/A
Altman-Z 0.28
ROIC/WACC0.51
WACC5.19%
EUK.MI Yearly LT Debt VS Equity VS FCFEUK.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • EUK has a Current Ratio of 0.32. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.32, EUK is doing worse than 75.76% of the companies in the same industry.
  • EUK has a Quick Ratio of 0.32. This is a bad value and indicates that EUK is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.32, EUK is not doing good in the industry: 75.76% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.32
Quick Ratio 0.32
EUK.MI Yearly Current Assets VS Current LiabilitesEUK.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • EUK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -260.63%.
  • Looking at the last year, EUK shows a small growth in Revenue. The Revenue has grown by 4.81% in the last year.
  • Measured over the past years, EUK shows a decrease in Revenue. The Revenue has been decreasing by -0.94% on average per year.
EPS 1Y (TTM)-260.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475.86%
Revenue 1Y (TTM)4.81%
Revenue growth 3Y6.09%
Revenue growth 5Y-0.94%
Sales Q2Q%3.39%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EUK.MI Yearly Revenue VS EstimatesEUK.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
EUK.MI Yearly EPS VS EstimatesEUK.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2018 2019 0.01 0.02 0.03 0.04 0.05

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • EUK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EUK.MI Price Earnings VS Forward Price EarningsEUK.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • EUK's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.63
EUK.MI Per share dataEUK.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • EUK does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EUKEDOS SPA

BIT:EUK (1/26/2026, 7:00:00 PM)

0.685

-0.02 (-2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.98%
Ins Owner ChangeN/A
Market Cap15.58M
Revenue(TTM)51.30M
Net Income(TTM)-1.15M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.3
P/FCF N/A
P/OCF 2.68
P/B 0.54
P/tB 1.75
EV/EBITDA 9.63
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)0.26
OCFY37.29%
SpS2.26
BVpS1.28
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.65%
ROE -3.97%
ROCE 3.52%
ROIC 2.64%
ROICexc 2.69%
ROICexgc 3.14%
OM 9.8%
PM (TTM) N/A
GM 95%
FCFM N/A
ROA(3y)0.12%
ROA(5y)-0.11%
ROE(3y)0.54%
ROE(5y)-0.64%
ROIC(3y)2.58%
ROIC(5y)2.22%
ROICexc(3y)2.64%
ROICexc(5y)2.29%
ROICexgc(3y)3.08%
ROICexgc(5y)2.68%
ROCE(3y)3.43%
ROCE(5y)2.97%
ROICexgc growth 3Y-1.81%
ROICexgc growth 5Y0.32%
ROICexc growth 3Y-1.47%
ROICexc growth 5Y0.29%
OM growth 3Y-2.47%
OM growth 5Y3.88%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y0.24%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 2.94
Debt/FCF N/A
Debt/EBITDA 7.49
Cap/Depr 328.04%
Cap/Sales 40.87%
Interest Coverage 250
Cash Conversion 50.88%
Profit Quality N/A
Current Ratio 0.32
Quick Ratio 0.32
Altman-Z 0.28
F-Score5
WACC5.19%
ROIC/WACC0.51
Cap/Depr(3y)160.89%
Cap/Depr(5y)115.09%
Cap/Sales(3y)22.9%
Cap/Sales(5y)16.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-260.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475.86%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.81%
Revenue growth 3Y6.09%
Revenue growth 5Y-0.94%
Sales Q2Q%3.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.09%
EBIT growth 3Y3.47%
EBIT growth 5Y2.9%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-480.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.86%
OCF growth 3Y20.95%
OCF growth 5Y10.45%

EUKEDOS SPA / EUK.MI FAQ

Can you provide the ChartMill fundamental rating for EUKEDOS SPA?

ChartMill assigns a fundamental rating of 1 / 10 to EUK.MI.


What is the valuation status for EUK stock?

ChartMill assigns a valuation rating of 0 / 10 to EUKEDOS SPA (EUK.MI). This can be considered as Overvalued.


What is the profitability of EUK stock?

EUKEDOS SPA (EUK.MI) has a profitability rating of 4 / 10.


How financially healthy is EUKEDOS SPA?

The financial health rating of EUKEDOS SPA (EUK.MI) is 1 / 10.